Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Core Insights - Gain Therapeutics has completed full enrollment of its Phase 1b study for GT-02287 in Parkinson's Disease earlier than expected, with results anticipated in Q4 2025 [1][12] - The company raised approximately $7.1 million in net proceeds from a public offering, extending its cash runway [1][12] - The Phase 1b study aims to evaluate the safety and tolerability of GT-02287, with a total enrollment capped at 20 participants [2][13] Clinical Program Highlights - The Phase 1b study has enrolled 16 patients as of June 30, 2025, with the possibility of including additional participants screened before July 31 [2][12] - The company has submitted a request to extend the dosing duration of the Phase 1b study beyond the original 90 days, with an update expected soon [2][3] - Preclinical data presented at various conferences indicate GT-02287's potential to modify disease progression in Parkinson's models [4][10] Financial Results - Research and Development (R&D) expenses decreased by $1.7 million to $2.8 million for Q2 2025 compared to $4.4 million in Q2 2024, attributed to grant income and optimized costs [6] - General and Administrative (G&A) expenses also decreased by $1.4 million to $2.3 million for Q2 2025 compared to $3.7 million in Q2 2024, mainly due to reduced stock-based compensation [7] - The net loss for Q2 2025 was $0.19 per share, down from $0.42 per share in Q2 2024, with cash and cash equivalents at $6.7 million as of June 30, 2025 [8][19] Upcoming Milestones - Analysis of functional changes and biomarker activity from the Phase 1b study is expected in Q4 2025 [1][12] - The company anticipates submitting an Investigational New Drug (IND) application to the FDA by the end of 2025 to facilitate Phase 2 clinical development [12]